Pierre E. Elisca

Array ( [id] => 13387251 [patent_doc_number] => 20180245167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => METHOD FOR EVALUATION OF VIABILITY OF VIRUSES WITH LYMPHOTROPISM PROPERTIES [patent_app_type] => utility [patent_app_number] => 15/966513 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986499 [patent_doc_number] => 20190062407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => AGENTS FOR INFLUENZA NEUTRALIZATION [patent_app_type] => utility [patent_app_number] => 15/959430 [patent_app_country] => US [patent_app_date] => 2018-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15959430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16539226 [patent_doc_number] => 20200405639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => NOVEL DELIVERY OF LARGE PAYLOADS [patent_app_type] => utility [patent_app_number] => 16/604711 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18837724 [patent_doc_number] => 11845787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => DNA antibody constructs for use against HIV [patent_app_type] => utility [patent_app_number] => 16/497945 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 23 [patent_no_of_words] => 34798 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 260 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16497945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16908081 [patent_doc_number] => 11040098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Influenza virus mutants and uses therefor [patent_app_type] => utility [patent_app_number] => 15/917926 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 77 [patent_no_of_words] => 29426 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15917926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519593 [patent_doc_number] => 20180311339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection [patent_app_type] => utility [patent_app_number] => 15/909112 [patent_app_country] => US [patent_app_date] => 2018-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88019 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15909112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17497771 [patent_doc_number] => 11286464 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Viral vaccines and methods of forming the same [patent_app_type] => utility [patent_app_number] => 15/906685 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 21 [patent_no_of_words] => 6943 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15906685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14243719 [patent_doc_number] => 10272042 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment [patent_app_type] => utility [patent_app_number] => 15/897025 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 14045 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13734035 [patent_doc_number] => 20180371485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => CHLOROPLASTS ENGINEERED TO EXPRESS PHARMACEUTICAL PROTEINS [patent_app_type] => utility [patent_app_number] => 15/889710 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145137 [patent_doc_number] => 20190351046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => UNIVERSAL INFLUENZA VACCINE TARGETING VIRUS/HOST RECOGNITION [patent_app_type] => utility [patent_app_number] => 16/483103 [patent_app_country] => US [patent_app_date] => 2018-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840571 [patent_doc_number] => 20190023770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/874758 [patent_app_country] => US [patent_app_date] => 2018-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39810 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15874758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12769984 [patent_doc_number] => 20180148496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => ANTI-PRE-S1 HBV ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/864494 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15864494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17074892 [patent_doc_number] => 11111277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Influenza vaccines [patent_app_type] => utility [patent_app_number] => 15/857436 [patent_app_country] => US [patent_app_date] => 2017-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 38229 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15857436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145139 [patent_doc_number] => 20190351047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => HENIPAVIRUS VACCINE [patent_app_type] => utility [patent_app_number] => 16/471541 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145133 [patent_doc_number] => 20190351044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => LASSA VIRUS VACCINE [patent_app_type] => utility [patent_app_number] => 16/471544 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641268 [patent_doc_number] => 20180105587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => BINDING MOLECULES TARGETING PATHOGENS [patent_app_type] => utility [patent_app_number] => 15/851272 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15851272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14994223 [patent_doc_number] => 20190316069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => ANTIGEN PRESENTING SCAFFOLDS FOR IMMUNE-CELL MANIPULATION [patent_app_type] => utility [patent_app_number] => 16/470503 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808747 [patent_doc_number] => 20180161419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => METHODS FOR IMPROVING THE EFFICACY OF VACCINE ANTIGENS [patent_app_type] => utility [patent_app_number] => 15/847694 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15847694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18051623 [patent_doc_number] => 11524994 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => Antibodies to human respiratory syncytial virus protein F pre-fusion conformation and methods of use therefor [patent_app_type] => utility [patent_app_number] => 16/470604 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 21 [patent_no_of_words] => 23394 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273801 [patent_doc_number] => 20190134185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => UNIVERSAL INFLUENZA VACCINE BASED ON HETEROLOGOUS MULTIPLE M2E PROTEINS [patent_app_type] => utility [patent_app_number] => 15/841556 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15841556 [rel_patent_id] =>[rel_patent_doc_number] =>)